FMP

FMP

Enter

BIOC - Biocept, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/BIOC.png

Biocept, Inc.

BIOC

NASDAQ

Inactive Equity

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

0.435 USD

-0.0701 (-16.12%)

About

ceo

Mr. Darrell Taylor Esq.

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

NASDAQ

Description

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cel...

CIK

0001044378

ISIN

US09072V6002

CUSIP

09072V402

Address

9955 Mesa Rim Road

Phone

858 320 8200

Country

US

Employee

50

IPO Date

Feb 5, 2014

BIOC Financial Summary

CIK

0001044378

Exchange

NASDAQ

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

09072V402

ISIN

US09072V6002

Country

US

Price

0.43

Beta

0.59

Volume Avg.

2.16M

Market Cap

0

Shares

-

52-Week

0.32-27.0

DCF

2.96

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.01

P/B

-

Website

https://biocept.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BIOC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep